Although direct electrophysiological evidence of SD in patients with migraine is still lacking, SD has attracted considerable attention for its translational relevance [
45]. Experimental models of SD have recapitulated multiple clinical characteristics of migraine in human subjects and have been used to explore the basic mechanisms, genetic and hormonal modulators, and potential physiological or pharmacological inhibitors of migraine [
45,
46]. SD susceptibility is one measure used to examine such relationships. The study of SD susceptibility involves the exploration of the vulnerability of brain tissues to occurrence, propagation and recurrence. Depending on the detection method, various SD susceptibility measurements have been used to study the physical and biochemical attributes of SD [
45,
47]. The stimulus intensity used to evoke SD is one of the most relevant attributes of SD susceptibility. Depending on the modality, stimulus intensity threshold can be measured in electrical charge intensity, volume or concentration of a depolarizing agent, or mechanical pressure. Another commonly measured SD susceptibility attribute is the frequency of SDs triggered during continuous topical application of suprathreshold concentrations of depolarizing agents. Propagation speed is also a reliable measure of SD susceptibility, and has good correlation with the threshold and frequency of SD [
47]. Other SD attributes such as amplitude and duration do not correlate well with susceptibility [
47]. Observations of SD susceptibility suggest sex and genetic variables associated with migraine alter the brains vulnerability to SD generation. For instance, there seems to be a reduced threshold for SD in female mice [
48], which fits with the observation that migraineurs are predominantly female.
Cacna1aR192Q knock-in (KI) mice that carry the human pathogenic familial hemiplegic migraine 1 (FHM1) R192Q mutation express an abnormally low SD threshold [
49], consistent with the notion that the brains of migraineurs are hyperexcitable [
50,
51]. In addition, clinically efficacious migraine prophylactic drugs, despite their different mechanisms, all inhibit SD susceptibility in vivo [
47,
52,
53]. Aging is also known to modulate SD susceptibility, which declines with senescence. However, despite reduced SD susceptibility, the consequences of SD recurrence in the older brains are more detrimental than that in younger brains [
54].